Jaekyung Cheon

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo, Kyu‐pyo Kim, Jae Ho Jeong et al. · The Lancet Oncology · 2021 · 220 citations

Medicine, Oncology, Pharmacology +14

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku et al. · Clinical Cancer Research · 2019 · 212 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 130 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)

Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 124 citations · Full text

Medicine, Oncology, Pharmacology +12